P-345. Prevalence of Integrase HIV-1 Drug Resistance Mutations in the United States: 2019-2024
Cassidy Henegar, Vani Vannappagari, Kimberley Brown(Janssen (Belgium)), Gayathri Sridhar, Charles Walworth(Laguna Research), Bryn Jones(ViiV Healthcare (Spain)), Johnny Lai, Mark Underwood, Annemiek de Ruiter(ViiV Healthcare (Spain))
Cited by 0
Related Papers
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen
|The Lancet|1996|631
Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011
|AIDS|2014|397
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
|AIDS|2002|359
A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population
|Infectious Diseases and Therapy|2018|197